ArticleNature communications2026

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

Isabel Soria-Bretones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.